Project Grant R01CA308360
Award Date 7/6/26
Completion Date 6/30/31
Dollars Obligated $522K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15213, USA
Similar Awards
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $395,846 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, with a completion date of March 31, 2031. The award supports research investigating the therapeutic targeting of SMARCAL1 (annealing helicase) as a synthetic lethal vulnerability in alternative lengthening of telomeres (ALT)-positive cancers, specifically...
- Federal Project Grant Award Summary The University of Pennsylvania received a $135,637 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded June 15, 2026, with a completion date of May 31, 2028. This award supports research training and workforce development in cancer biology, specifically investigating the molecular mechanisms of Alternative Lengthening of Telomeres (ALT) as an alternative telomere maintenance pathway used by...
- Federal Grant Award Summary Carnegie Mellon University's Office of Sponsored Programs received a $197,600 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) awarded on September 10, 2025, with an ultimate completion date of May 15, 2028. The project, titled "Free Energy-Based Active Learning for Ligand Off-Target and Multitarget Activity," delivers computational research and methodology development focused on predicting...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $673,522 to the University of Pittsburgh under the Cancer Cause and Prevention Research program (CFDA 93.393) for a five-year project grant beginning July 1, 2026, and concluding June 30, 2031. Under the direction of Principal Investigator Orlando Scharer, this project will deliver comprehensive research on the dynamic processing of DNA lesions by human nucleotide excision repair (NER), a critical cellular pathway for...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a $630,089 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective May 1, 2026, through April 30, 2031. This award funds research to characterize the molecular functions of SMARCAL1, a DNA translocase protein involved in regulating anti-tumor immune responses. The research addresses a critical gap in cancer immunotherapy by...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a $3.2 million Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) beginning August 1, 2025, and concluding July 31, 2029. This research initiative investigates the mechanisms of extrachromosomal DNA (ecDNA) segregation and repair in cancer cells, with emphasis on understanding how ecDNA's circular topology contributes to tumor progression...
- Federal Project Grant Award Summary The University of Chicago received a $464,212 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) awarded on August 1, 2025, with a completion date of July 31, 2030. This five-year project supports research characterizing cancer susceptibility mechanisms associated with the TERT/CLPTM1L locus at chromosome 5p15.33, a highly pleiotropic genetic region linked to increased risk for over 15...
- Federal Grant Award Summary The National Cancer Institute awarded a $736,168 Project Grant to Sloan-Kettering Institute for Cancer Research (award date: August 1, 2025; completion date: July 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) designed to enhance radiotherapy efficacy through antigen-specific radiosensitization. The research focuses on delivering potent DNA damage...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $388,439 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded July 8, 2026, with completion targeted for June 30, 2028. The project delivers two genetically engineered cell reporter platforms designed to detect and monitor the Alternative Lengthening of Telomeres (ALT) pathway, a critical pediatric cancer biomarker. The first...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $323,860 to Sloan-Kettering Institute for Cancer Research on August 18, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support research investigating the role of mutagenic DNA repair during cancer cell persistence. The research will examine how cancer cells under stress from anti-cancer drug exposure shift their reliance from error-free DNA repair pathways—such as homologous recombination (HR)—to...